On July 16, Ali Health rose 3.27% in regular trading, trading at HK$3.44/share, with turnover of approximately HK$98.43 million.

On the news front, the medical e-commerce sector entered a recovery phase following two consecutive days of sharp selling. Ali Health had touched a low of HK$3.16 on July 14, closely approaching UBS's HK$3.1 sell target price, before attracting buying support and rebounding for a second straight session. The broader Internet and direct marketing retail sector strengthened collectively, with Alibaba up 3.35%, Meituan up 3.18%, and JD Health up 2.24%, providing sector-wide momentum.

Additionally, Bank of America Securities and Jefferies previously maintained buy ratings on Ali Health with target prices of HK$5.1 and HK$5.3 respectively, well above the current share price, with some funds continuing to accumulate on weakness amid the valuation gap.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)